ANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Analysts at HC Wainwright

Equities research analysts at HC Wainwright initiated coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) in a research note issued on Thursday, Marketbeat.com reports. The brokerage set a "buy" rating and a $84.00 price target on the specialty pharmaceutical company's stock. HC Wainwright's price target indicates a potential upside of 29.31% from the company's previous close.

Other equities research analysts have also issued reports about the stock. JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price objective for the company. Wall Street Zen downgraded ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They set a "buy" rating and a $80.00 price objective for the company. Guggenheim reaffirmed a "buy" rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. Finally, Truist Financial upped their price target on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research report on Monday, April 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $78.88.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP traded down $1.14 on Thursday, hitting $64.96. The stock had a trading volume of 218,680 shares, compared to its average volume of 316,993. The company has a quick ratio of 1.98, a current ratio of 2.66 and a debt-to-equity ratio of 1.46. The stock has a market cap of $1.41 billion, a price-to-earnings ratio of -51.15 and a beta of 0.57. The business's 50-day simple moving average is $63.31 and its two-hundred day simple moving average is $62.37. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.33. The company had revenue of $197.12 million for the quarter, compared to the consensus estimate of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. ANI Pharmaceuticals's quarterly revenue was up 43.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.82 earnings per share. As a group, research analysts predict that ANI Pharmaceuticals will post 3.86 earnings per share for the current year.

Insiders Place Their Bets

In related news, VP Meredith Cook sold 400 shares of the stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $68.96, for a total value of $27,584.00. Following the transaction, the vice president owned 80,145 shares in the company, valued at approximately $5,526,799.20. This represents a 0.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Christopher Mutz sold 4,000 shares of the stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total transaction of $241,800.00. Following the completion of the sale, the insider owned 107,317 shares in the company, valued at $6,487,312.65. The trade was a 3.59% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 5,681 shares of company stock valued at $346,854. 12.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals in the first quarter worth about $28,000. US Bancorp DE boosted its stake in ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after buying an additional 531 shares during the last quarter. National Bank of Canada FI purchased a new stake in shares of ANI Pharmaceuticals in the first quarter valued at about $79,000. GAMMA Investing LLC increased its holdings in shares of ANI Pharmaceuticals by 163.8% during the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after buying an additional 881 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in ANI Pharmaceuticals in the fourth quarter valued at $166,000. Institutional investors and hedge funds own 76.05% of the company's stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.